ASGCT News   |   Molecular Therapy

Molecular Therapy Impact Factors Jump Nearly 28 Percent Across Family of Titles

ASGCT Staff - June 26, 2019

Parent journal, Molecular Therapy, now tops the field with a 19.9 percent jump in impact factor to 8.402.

The latest impact factor scores for the Molecular Therapy family of journals, the official journals of the American Society of Gene & Cell Therapy (ASGCT), rose by a collective average of 27.9 percent when released on Thursday, June 20.

Impact factors, which measure the frequency with which an average article has been cited in a journal, rank research titles against one another to determine leading journals around the world.

The impact factor of Molecular Therapy, ASGCT’s first and primary journal, rose 19.9 percent to 8.402 and remains the top journal in the field. Elsewhere in the Molecular Therapy family, Molecular Therapy–Oncolytics and Molecular Therapy–Methods & Clinical Development earned the largest percentage increases (54.7 and 32.4 percent, respectively) across publisher Cell Press’ entire portfolio. Oncolytics also jumped 48 places in overall rank in the Oncology category, from a rank of 85 to 37. The Molecular Therapy family of journals are now the top-ranked journals in the field.

Overall growth in the Molecular Therapy family of journals are as follows:

  • Molecular Therapy: 8.402 (+19.9 percent)
  • Molecular Therapy-Nucleic Acids: 5.919 (+4.6 percent)
  • Molecular Therapy-Oncolytics: 5.71 (+54.7 percent)
  • Molecular Therapy-Methods & Clinical Development: 4.875 (+32.4 percent)

Share This Page

Related Articles

Molecular Therapy

Molecular Therapy Family's Impact Factor Increased 44 Percent in 2020

ASGCT Staff - July 01, 2021
ASGCT News

ASGCT Statement of Support for the Asian, Asian-American and Pacific Islander Communities

ASGCT Board of Directors - April 27, 2021
ASGCT News

Gene, Cell, & RNA Therapy Landscape: Q1 2021

David M. Barrett, J.D., M.S. - April 15, 2021
ASGCT News

New Diversity and Inclusion Awards Aim to Promote Equity in Gene and Cell Therapy Research

David Barrett, J.D., M.S. - February 26, 2021